Based in Bothell, Washington, the laboratory has belonged to TD2, the Scottsdale-based oncology development group, since an acquisition completed in February 2024 that followed eight years of collaborative project work. It holds College of American Pathologists accreditation for immunophenotyping of human common lymphocyte subsets and publishes its CAP test menu. Panels reach from standard immunophenotyping through intracellular marker detection, with antibody combinations built to order. Receptor occupancy is measured by direct or indirect methods, and full cell culture capability supports functional readouts such as natural killer cell activity and the Basophil Activation Test. PBMC separation is available where an assay calls for it. Instruments include higher-dimensional spectral cytometers, and projects span exploratory research, preclinical GLP studies and clinical trial sample testing, with experience in both straightforward and complex gating strategies.
Flow Contract Site (FCS) Laboratory
Flow Contract Site (FCS) Laboratory is a highly specialized contract research organization focused exclusively on flow cytometry assay development, validation, and sample analysis for clinical trials. Serving the biopharmaceutical industry, FCS Laboratory provides robust immune profiling, receptor occupancy testing, and cellular analysis under strict regulatory standards to support pipeline progression.
